JPS6354399A - Immobilization of antibody protein with lipid monomolecular film - Google Patents
Immobilization of antibody protein with lipid monomolecular filmInfo
- Publication number
- JPS6354399A JPS6354399A JP19722086A JP19722086A JPS6354399A JP S6354399 A JPS6354399 A JP S6354399A JP 19722086 A JP19722086 A JP 19722086A JP 19722086 A JP19722086 A JP 19722086A JP S6354399 A JPS6354399 A JP S6354399A
- Authority
- JP
- Japan
- Prior art keywords
- antibody protein
- water
- monomolecular film
- complex
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 150000002632 lipids Chemical class 0.000 title abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 13
- 239000000758 substrate Substances 0.000 claims abstract description 12
- 229910052751 metal Inorganic materials 0.000 claims abstract description 6
- 239000002184 metal Substances 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 13
- 230000003100 immobilizing effect Effects 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000013554 lipid monolayer Substances 0.000 claims description 2
- 230000005501 phase interface Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 4
- 239000012153 distilled water Substances 0.000 abstract description 4
- 235000021353 Lignoceric acid Nutrition 0.000 abstract description 3
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 abstract description 3
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明は抗体タンパクを固定化する方法に関する。更に
詳しくは、水溶性抗体タンパクを、その・ 抗原−抗体
反応活性を完全に保持しながら固体基板−りに該タンパ
クを高密度に固定化する方法に関lる。DETAILED DESCRIPTION OF THE INVENTION <Industrial Application Field> The present invention relates to a method for immobilizing antibody proteins. More specifically, the present invention relates to a method of immobilizing a water-soluble antibody protein at high density on a solid substrate while completely retaining its antigen-antibody reaction activity.
く背景及び従来技術〉
抗体タンパクの抗原−抗体反応を利用した診断技術に於
て、抗体タンパクを固体基板上に固定化する方法がこれ
まで数多く提案されてきた。これらの内、あるものは、
抗体タンパクのアミノ基又はカルボキシル基と反応又は
吸着結合できる官能基を右する固体表面に固定化するも
のであるが、この場合、固定化のための反応条件の設定
によっては、抗体タンパクの変性や、非特異的反応によ
る活性部位の失活が起りやすいという問題点があった。Background and Prior Art In diagnostic techniques that utilize antigen-antibody reactions of antibody proteins, many methods have been proposed to date for immobilizing antibody proteins on solid substrates. Some of these are
Functional groups that can react with or adsorb and bond with amino groups or carboxyl groups of antibody proteins are immobilized on the solid surface, but in this case, depending on the setting of reaction conditions for immobilization, denaturation or denaturation of the antibody proteins may occur. However, there was a problem in that the active site was easily deactivated due to non-specific reactions.
また、親水性ゲルの中に抗体タンパクを抱き込ませて、
固体基板上に固定化する方法も可能性のある方法である
が、この場合、抗原タンパクがゲル中の抗体タンパクに
接近て“き難くなり、抗原−抗体反応を利用した診断材
料としての感度低下を招き易い。こうした方法に対して
近年、水面上に脂質膜を展開し、これに水中から水溶性
酵素(例、カタラーゼ、フェリチン、ヘミグロビン。In addition, by incorporating antibody proteins into a hydrophilic gel,
Immobilization on a solid substrate is also a possible method, but in this case, the antigen protein approaches the antibody protein in the gel, making it difficult for it to be detected, resulting in a decrease in sensitivity as a diagnostic material using antigen-antibody reactions. In recent years, these methods have been developed by deploying a lipid membrane on the water surface and then introducing water-soluble enzymes (e.g., catalase, ferritin, hemiglobin) from the water.
グルコースオキシダーゼ、etc、)や抗体タンパク[
免疫グ[1プリンG (HUG)、 IgE、 etc
]を吸着固電化づ−る試みか報告されている(バイオキ
ミカ・エト・バイオフィジカ・アクタ(8iochem
、 Bio−pt)ys、 Aeta、) 225ff
、 382 (1971)やジャーナル・オブ・セルラ
〜 ・バイオケミス]〜リー (J、 Ce1l。glucose oxidase, etc.) and antibody proteins [
Immunogen [1 Purine G (HUG), IgE, etc.
] has been reported to be an attempt to adsorb and convert it into a solid charge (Biochem.
, Bio-pt)ys, Aeta,) 225ff
, 382 (1971) and Journal of Cellular Biochemistry] Lee (J, Ce1l.
Bioct+em、) 29.239 (1985)等
参照]。Bioct+em, ) 29.239 (1985), etc.].
これらは確か(こタンパクを、その活性を保持したまま
固定化する優れた方法であるが、この方法に於て従来用
いられてきた脂質膜は、ステアリン酸、アラキン酸及び
ジパルミトイルホスファデジルコリン(D P P C
>等の如く、水に対して可溶t4. (少くとも、1μ
g/IJ2水の溶解度)のもの、又は水中で二分子膜ベ
シクルを形成しやすいもの(DPPC等)であった。従
って、水面上で該膜に吸着された抗体タンパクは、時間
が経つにつれ、脂質膜と共に再び水中に再溶解したり、
−旦固体M板上に累積した後でも抗原水溶液に浸漬した
際、脱witノやすいという問題点を有していた。These are certainly excellent methods for immobilizing proteins while retaining their activity, but the lipid membranes conventionally used in this method are made of stearic acid, arachidic acid, and dipalmitoylphosphadecylcholine. (D P P C
> etc., t4. (At least 1μ
g/IJ2 water solubility), or those that easily form bilayer membrane vesicles in water (such as DPPC). Therefore, over time, the antibody protein adsorbed to the membrane on the water surface may be redissolved in the water together with the lipid membrane, or
- Even after being accumulated on the solid M plate, there was a problem in that it was easily dewitted when immersed in an aqueous antigen solution.
〈発明の目的〉
本発明者らは、かかる従来技術の欠点を克服し、高い抗
原−抗体反応活性の保持率と、高密度な抗体タンパクの
固定化を可能に1べく鋭意検84のII!i果、本発明
に到達したしのである。<Objective of the Invention> The present inventors have overcome the drawbacks of the prior art and have conducted extensive research to achieve a high retention rate of antigen-antibody reaction activity and immobilization of antibody proteins at high density. As a result, we have arrived at the present invention.
〈発明の開示〉
すなわら本発明は、水相面1、に展開された炭素原子数
24〜32の長鎖脂肪酸、その多価金属塩及び/又はそ
のエステルの単分子膜に当該水相中に溶解した水溶性抗
体タンパクを接触させることにより当該水相界面で抗体
タンパク−単分子膜複合体を形成させ、それを固体基板
上に積層することを特徴と覆る脂質中分子膜を用いた抗
体タンパクの固定化方法である。<Disclosure of the Invention> In other words, the present invention provides a monomolecular film of a long-chain fatty acid having 24 to 32 carbon atoms, a polyvalent metal salt thereof, and/or an ester thereof developed on the aqueous phase surface 1. By contacting the water-soluble antibody protein dissolved in the solution, an antibody protein-monolayer complex is formed at the aqueous phase interface, and this is layered on a solid substrate using a covering lipid medium molecule membrane. This is a method for immobilizing antibody proteins.
本発明でいう抗体タンパクとは、抗原−抗体反応を起l
ノうる水溶性タンパクの総称であり、その分子中に抗原
認識部位(Fabと略)と疎水性末端部位(FCと11
8)を心している。In the present invention, the antibody protein refers to a protein that causes an antigen-antibody reaction.
It is a general term for water-soluble proteins that contain an antigen recognition site (abbreviated as Fab) and a hydrophobic terminal site (FC and 11
8).
かかる抗体タンパクの具体例としては、免疫グロブリン
G(IgGと略称) 、 ■gE 、 IgH及びこれ
らの抗体、絨毛性性腺刺激ホル−[ン()−I CG
>抗体、ガン胎児性抗原(CEA)抗体等があげられる
。Specific examples of such antibody proteins include immunoglobulin G (abbreviated as IgG), gE, IgH and antibodies thereof, and chorionic gonadotropin ()-ICG.
> antibodies, carcinoembryonic antigen (CEA) antibodies, etc.
これらの抗体タンパクの固定化にあたっては、Fab部
分を変性しないようにすることが肝要であるが、萌述の
如〈従来の化学反応による固定化の場合Fab部分も反
応に関与して抗体タンパクの活性低下を招いていた。本
発明においては抗体タンパクは、後述の脂質単分子膜中
にFC部位で疎水的に相U作用しながら高密度にくみ込
まれるか、イイン的相互作用により免疫活性を高く保持
したまま単分子膜に吸着固定される。When immobilizing these antibody proteins, it is important to prevent the Fab portion from denaturing; however, as mentioned above, in the case of immobilization by conventional chemical reactions, the Fab portion also participates in the reaction and denatures the antibody protein. This resulted in a decrease in activity. In the present invention, the antibody protein is packed into a lipid monolayer (described later) at high density while interacting with the FC site hydrophobically, or the antibody protein is incorporated into the monolayer membrane while maintaining high immunoactivity due to the FC site. It is fixed by suction.
上記の抗体タンパクを固定化するための脂質単分子膜と
しては、水面上で固体上の凝縮単分子膜を形成し、水に
実質的に溶解しないものが好ましい。そのようなものの
具体例としては、炭素原子数24〜32の長鎖脂肪酸、
その多価金属塩及び/又はその上スプルが用いられる。The lipid monomolecular film for immobilizing the antibody protein described above is preferably one that forms a solid condensed monomolecular film on the water surface and does not substantially dissolve in water. Specific examples of such substances include long chain fatty acids having 24 to 32 carbon atoms;
The polyvalent metal salt and/or the sprue are used.
このような性質を有する化合物としては、リグノセリン
酸(C23H47COOH)、セロチン酸(C25H5
1COOH)。Compounds with such properties include lignoceric acid (C23H47COOH) and cerotic acid (C25H5
1 COOH).
モンタン酸(C2□l−!55Goof−1>、メリシ
ン酸(C29)−159COOI−1> 、ラクセロン
酸(C31H63COOH) 及びC口 ト12n+I
C00M (n =23〜31、M−アルカリ
土類金属、カドミウム、アルミニウム等の多価金属イオ
ン)で表わされる長鎖脂肪酸の多価金属塩及びそれら脂
肪酸のメタノール又はエタノールとのエステルである。Montanic acid (C2□l-!55Goof-1>, Melisic acid (C29)-159COOI-1>, Laceronic acid (C31H63COOH) and C12n+I
They are polyvalent metal salts of long-chain fatty acids represented by C00M (n = 23-31, M - polyvalent metal ions such as alkaline earth metals, cadmium, aluminum, etc.) and esters of these fatty acids with methanol or ethanol.
これらは例えばカルボン酸又はそのエステルの状態で
ベンじンやクロロホルム等の有機溶媒に溶解させ、0.
5〜1.5ミリモル/1の溶液となしたのら、これを蒸
溜水又は多価金属塩(例えば、塩化バリウム、塩化カド
ミウム、塩化アルミニウム)を含む、pt16.5〜7
.5の水溶液表面上に展開することにより、単分子膜と
なしうる。次いで、該単分子膜を、その表面ルノJか1
〜30mN (ミリN)/mになるように圧縮したのら
、そのままの圧縮条f↑で膜面下の水相に前記の抗体タ
ンパクを注入する。所定時間(通常、30分〜1時間)
、該抗体タンパクと水面上の単分子膜とを接触させてお
くことにより、タンパクと該単分子膜との複合化が完了
する。この時点で抗体タンパクと単分子膜との複合体膜
を、表面圧力30〜50ミリN/mにて再び圧縮したの
ら、固体基板上にラングミュア・ブロジエツ1〜法又は
水平付着法(詳1111は新実験化学講Pト第18巻第
439頁参照)により一苦又は複数層積層することがで
きる。These are dissolved, for example, in the form of carboxylic acid or its ester in an organic solvent such as benzene or chloroform.
After making a solution of 5 to 1.5 mmol/1, add distilled water or a solution containing polyvalent metal salts (e.g., barium chloride, cadmium chloride, aluminum chloride), pt16.5 to 7.
.. By spreading it on the surface of the aqueous solution of No. 5, a monomolecular film can be formed. Then, the monolayer was coated with a
After compressing to ~30 mN (milliN)/m, the above-mentioned antibody protein is injected into the aqueous phase below the membrane surface using the same compressed force f↑. Specified time (usually 30 minutes to 1 hour)
By bringing the antibody protein into contact with the monomolecular film on the water surface, the complexation between the protein and the monomolecular film is completed. At this point, the composite film of antibody protein and monolayer is compressed again at a surface pressure of 30 to 50 mmN/m, and then deposited on a solid substrate using the Langmuir-Brosietz method or the horizontal adhesion method (Details 1111). (Refer to Shin Jikken Kagaku Koko Volume 18, page 439), one or more layers can be laminated.
その際の抗体タンパクの固体基板上への固定化量は、積
層時の水面展開膜の基板への転移比及びLJ V−−吸
収スペクトル強度より算出される。At this time, the amount of antibody protein immobilized on the solid substrate is calculated from the transfer ratio of the water surface spreading film to the substrate during lamination and the LJ V-- absorption spectrum intensity.
かくして(■られた基板上の複合体は、抗体タンパクの
抗卯−抗体反応活性を酵素免疫診断法(EIA)により
求めた結束、1ぐれた活性を示づものであった。The complex on the substrate thus obtained (1) showed superior activity in terms of unity and activity determined by enzyme immunodiagnosis (EIA) for the anti-rabbit-antibody reaction activity of the antibody protein.
以下、実施例により本発明を更に詳しく説明する。Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例1
リグノセリンW (C23H47COi41 ) 8
m(Jを25m1の蒸d1り[J口車ルムに溶解し蒸溜
水を張った。π−△測定用水槽上に上記溶液100μl
を徐々に滴下した。滴下終了後、水面展間膜を5分間静
置した後人面圧20mN/mになるまで仕切板を移動し
た。Example 1 Lignocerin W (C23H47COi41) 8
Dissolve J in 25 ml of distilled water and fill with distilled water. Place 100 μl of the above solution on the π-△ measurement water tank.
was gradually added dropwise. After dropping, the membrane was allowed to stand still for 5 minutes, and then the partition plate was moved until the surface pressure reached 20 mN/m.
ヒt−IgG水溶液を水槽中濃度0.03mM rnl
になるように水中から注入した後1時間静置した。この
水面FI= (M膜を、30mN/mの表面LF下で圧
縮しながら、疎水化処理(シランカップリング処理)を
施した石英板上に垂直浸漬用−1,げ法(以下、l−B
法と称覆−)により2層累積しノた処、平均累積比は0
.7であった。紫外吸収スペクトルから求めた石英板上
に累積したヒh I(IGの被覆率は1.6 Xl0−
[1mol /尻であった。この累積膜にベルオキシタ
ーゼ標識抗ヒ1〜IgG抗体(20μm/d)液を作用
させた後、オルトフェニレンジアミン、過酸化水素混合
溶液中に浸漬して累積膜中の抗原活性を調べた処、活性
を保持していることがわかった。Human-IgG aqueous solution in a water tank at a concentration of 0.03mM rnl
After injecting from water so that While compressing this water surface FI=(M membrane under a surface LF of 30 mN/m, it was placed on a quartz plate that had been subjected to hydrophobization treatment (silane coupling treatment) using the vertical immersion method (hereinafter referred to as l- B
The average cumulative ratio is 0 when two layers are accumulated due to the law and subversion.
.. It was 7. The amount of heat accumulated on the quartz plate determined from the ultraviolet absorption spectrum (the coverage of IG is 1.6 Xl0-
[It was 1 mol/butt. After applying a peroxidase-labeled anti-human 1 to IgG antibody (20 μm/d) solution to this accumulated membrane, the antigen activity in the accumulated membrane was examined by immersing it in a mixed solution of orthophenylenediamine and hydrogen peroxide. It was found that it retained its activity.
実施例2
実施例1に於て、リグノセリン酸を用いる代りに、ラク
セロンv、、(C311−163COO[−1)ヲ用イ
テ水面展間膜を形成し水中よりヒI−IgGを吸右させ
たのら、石英ガラス基板上に累積した処、平均累積比は
0.82であった。また、実施例1と同様にしてこのも
のの抗原活性を調べた処、水中に溶解しているI(IG
と同じ程度の高い活性を保持していた。Example 2 In Example 1, instead of using lignoceric acid, a water surface-extending film was formed using luxelon v, (C311-163COO[-1) to absorb H-IgG from water. When accumulated on a quartz glass substrate, the average accumulation ratio was 0.82. In addition, when the antigenic activity of this product was investigated in the same manner as in Example 1, it was found that I (IG
It maintained the same high level of activity.
比較例1
ステアリン酸溶液を用いて実施例1と同様にして水面上
に単分子膜を展開し、その後、水中にヒ1−19Gを注
入した。5分間静置後、表面圧30ミリN/mを保つよ
う仕切り板を移動させた処、水面展間膜の面積は減少し
続け、ステアリン酸のIC1G水溶液中への部分溶解か
見られた。この水面展開膜を、石英ガラス板上にLB法
によつ−C2層累積した処、ぞの累積比は0.41と低
く、累積中に膜の部分的剥離が観察された。この膜の抗
原活性を実施例1と同様にして評価した処、水溶液状態
でのrgG活性の 173〜1/4に低下していた。Comparative Example 1 A monomolecular film was spread on the water surface using a stearic acid solution in the same manner as in Example 1, and then Hi1-19G was injected into the water. After standing still for 5 minutes, the partition plate was moved to maintain a surface pressure of 30 mmN/m, and the area of the water surface membrane continued to decrease, indicating partial dissolution of stearic acid into the IC1G aqueous solution. When this water surface spread film was deposited in two -C layers on a quartz glass plate by the LB method, the cumulative ratio was as low as 0.41, and partial peeling of the film was observed during the accumulation. The antigen activity of this membrane was evaluated in the same manner as in Example 1, and it was found to have decreased to 173 to 1/4 of the rgG activity in an aqueous solution state.
Claims (1)
酸、その多価金属塩及び/又はそのエステルの単分子膜
に当該水相中に溶解した水溶性抗体タンパクを接触させ
ることにより当該水相界面で抗体タンパク−単分子膜複
合体を形成させ、それを固体基板上に積層することを特
徴とする脂質単分子膜を用いた抗体タンパクの固定化方
法。By bringing a water-soluble antibody protein dissolved in the aqueous phase into contact with a monomolecular film of a long-chain fatty acid having 24 to 32 carbon atoms, its polyvalent metal salt, and/or its ester spread on the surface of the aqueous phase. A method for immobilizing an antibody protein using a lipid monolayer, which comprises forming an antibody protein-monolayer complex at the aqueous phase interface and stacking the complex on a solid substrate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19722086A JPS6354399A (en) | 1986-08-25 | 1986-08-25 | Immobilization of antibody protein with lipid monomolecular film |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19722086A JPS6354399A (en) | 1986-08-25 | 1986-08-25 | Immobilization of antibody protein with lipid monomolecular film |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6354399A true JPS6354399A (en) | 1988-03-08 |
JPH047759B2 JPH047759B2 (en) | 1992-02-12 |
Family
ID=16370833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP19722086A Granted JPS6354399A (en) | 1986-08-25 | 1986-08-25 | Immobilization of antibody protein with lipid monomolecular film |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6354399A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0494998A1 (en) * | 1989-10-10 | 1992-07-22 | Research Corporation Technologies, Inc. | Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof |
-
1986
- 1986-08-25 JP JP19722086A patent/JPS6354399A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0494998A1 (en) * | 1989-10-10 | 1992-07-22 | Research Corporation Technologies, Inc. | Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH047759B2 (en) | 1992-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6291155B1 (en) | Self assembly of sensor membranes | |
US4987032A (en) | Functional organic thin film and method of manufacture thereof | |
JPH08505123A (en) | Improved sensor membrane | |
JPH06122521A (en) | Method of obtaining interaction by sol-gel glass and said sol-gel glass | |
JPH07117536B2 (en) | Method for detecting specifically bindable substance in body fluid and ligand receptor | |
EP0106769B1 (en) | Surface-grafted particulate support, its preparation and adsorbents for affinity-chromatography comprising this support, and its use, especially in biology | |
JPH03505222A (en) | Method for immobilizing proteins, peptides, coenzymes, etc. on carriers | |
US4656252A (en) | Amidobiotin compounds useful in a avidin-biotin multiple layering process | |
Kim et al. | Immobilization methods for affinity chromatography | |
Caseli et al. | Enzymatic activity of alkaline phosphatase adsorbed on dimyristoylphosphatidic acid Langmuir–Blodgett films | |
JPS6354399A (en) | Immobilization of antibody protein with lipid monomolecular film | |
US5879878A (en) | Method of producing a first layer electrode membrane for a biosensor | |
JPS60155129A (en) | Preparation of immobilized antigen or antibody | |
JPH047760B2 (en) | ||
Damrongchai et al. | Calcium responsive two-dimensional molecular assembling of lipid-conjugated calmodulin | |
JPH0473749B2 (en) | ||
JP2922040B2 (en) | Method for immobilizing antibody protein with protein A molecular membrane and antibody immobilized membrane | |
Cabaj et al. | Biosensing invertase-based Langmuir–Schaefer films: Preparation and characteristic | |
US4950405A (en) | Functional thin organic membrane | |
JPH02272081A (en) | Functional organic thin film | |
JP3020428B2 (en) | Ultra-thin protein film formation by alternate adsorption method | |
JPH10506994A (en) | Biosensor with biological material covalently immobilized on a signal-active surface | |
JP3509142B2 (en) | Reactive liposomes and forming agents | |
Neumann-Spallart et al. | Immobilization of active facilitated glucose transporters (GLUT-1) in supported biological membranes | |
JP2957625B2 (en) | Optical sensor |